387 related articles for article (PubMed ID: 10051494)
1. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
2. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
3. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
5. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
6. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
7. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
8. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine as initial treatment for chronic hepatitis B in the United States.
Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
[TBL] [Abstract][Full Text] [Related]
10. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
11. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
12. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
13. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
Wolters LM; van Nunen AB; Niesters HG; de Man RA
Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
[TBL] [Abstract][Full Text] [Related]
14. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
15. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
16. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
17. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
18. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
19. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
Lu WL; Xie DY; Yao JL; Yao GB; Cui ZY; Zhang DF; Wu L
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
